Cargando…
Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
SIMPLE SUMMARY: In patients with relapsed or metastasized squamous cell cancer of the head and neck (R/M SCCHN), the PD-L1 Combined Positive Score (CPS) is currently the only predictive biomarker for treatment with anti-PD-1 agents. However, ambiguous results have been determined regarding the overa...
Autores principales: | De Keukeleire, Stijn Jeroen, Vermassen, Tijl, Deron, Philippe, Huvenne, Wouter, Duprez, Fréderic, Creytens, David, Van Dorpe, Jo, Ferdinande, Liesbeth, Rottey, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139955/ https://www.ncbi.nlm.nih.gov/pubmed/35626035 http://dx.doi.org/10.3390/cancers14102431 |
Ejemplares similares
-
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
por: De Meulenaere, Astrid, et al.
Publicado: (2021) -
Tumor PD-L1 status and CD8(+) tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
por: De Meulenaere, Astrid, et al.
Publicado: (2017) -
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021) -
Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?
por: Almangush, Alhadi, et al.
Publicado: (2022) -
The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
por: Cleymaet, Robbert, et al.
Publicado: (2022)